YHLO Newest IVDR Certificate Extended to 72 Products
In August 2022, YHLO received the newest IVDR Certificate from BSI, one of the most reputable notified bodies for medical device CE certifications. The IVDR certificate of YHLO covers additional 58 YHLO chemiluminescent immunoassay (CLIA) detection products including TSH, Cardiolipin IgG, AMH, CA 15-3, CK-MB, HSV-1 IgG etc. Until today, YHLO has obtained IVDR CE Certificate of 72 products, covering the autoimmunity, reproductive health, tumor markers, cardiac markers, infection detection fields and so forth.
The Regulation (EU) 2017/746 on in vitro diagnostic Medical Devices is the new EU legislation applicable to in vitro diagnostic (IVD) medical devices. As of 26 May 2022, the Regulation (EU) 2017/746 (IVDR) fully applied across the EU. The 58 newly certified products of YHLO are proving to the EU market that they are meeting the higher level of requirement to offer safe, high quality and effective diagnostic solutions to patients and healthcare professionals. The rest of YHLO’s other CLIA products are also under the process of obtaining the same certification in a smooth order.
In order to supply reliable products and services to customers, the YHLO team has been working hard to obtain the CE mark in accordance with the IVDR. With the mission of “Focus on healthcare, better life with technology”, YHLO will continue to provide reliable, high-quality healthcare innovations and services worldwide to improve human well-being.
Attachments:
Next Page
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
